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Abstract
Purpose: To investigate the efficacy of 0.1%, 0.15%, and 0.3% sodium hyaluronate (SH) artificial tears
compared with 0.05% cyclosporine (CS) ophthalmic solution for the treatment of dry eye.
Methods: One hundred seventy-six patients were recruited and randomized to receive of 0.1%, 0.15%, and
0.3% SH and 0.05% CS. There was a primary end point which is the changes in the fluorescein corneal staining
(FCS) score to determine noninferiority of 0.1%, 0.15%, and 0.3% SH. Secondary objective end points were
lissamine green conjunctival staining (LGCS) scores, Schirmer test, and tear film break-up time (TBUT).
Secondary subjective end point was ocular surface disease index (OSDI) score. These were evaluated before
treatment and 6 and 12 weeks after start of treatment.
Results: In the primary analysis, the mean change from baseline in FCS scores verified noninferiority of 0.1% and
0.15%SH to 0.05%CS and also indicated significant improvement of all groups (P< 0.05). Values for TBUT, LGCS
scores, andOSDI scores showed significant improvements in all groups (P< 0.05), although no significant intergroup
differencewas shown.However, Schirmer test scores in the 0.15%SHgroup showed a significant tendency for better
improvement at week 12 compared with the other groups (P< 0.05). No serious adverse events were observed.
Conclusions: Administration of 0.1%, 0.15%, and 0.3% SH was effective in improving both the objective signs
and subjective symptoms of dry eye. Those findings, in addition to the well-tolerated profile of 0.1%, 0.15%,
and 0.3% SH, show that it is effective therapeutic method for dry eye.
Keywords: dry eye syndrome, 0.1% sodium hyaluronate, 0.15% sodium hyaluronate, 0.3% sodium hyaluronate,
0.05% cyclosporine
Introduction
Dry eye is common, affecting*10%–20% of the pop-ulation.1 It is a multifactorial disorder of the tear film and
ocular surface, which results in ocular discomfort, visual dis-
turbance, and ocular surface damage. It is caused by disruption
of the ocular surface, driven by tear hyperosmolarity and tear
film instability.2 The tear filmcan be destabilized by decreased
tear production or altered tear composition, damaging the
ocular surface and resulting in inflammation.2 Dryness of the
ocular surface epithelium can induce apoptosis of epithelial
cells, which eventually leads to aggravation of dry eye.3
The current managements of dry eye include tear supple-
mentation, tear stimulation, anti-inflammatory agents, immu-
nomodulatoryagents, and environmental strategies.4Currently,
the main therapy for dry eye is artificial tears, with anti-
inflammatory therapyandpunctual occlusion therapyas second
and third line therapies.5
Sodium hyaluronate (SH) is a glycosaminoglycan with a
viscoelastic rheology and a natural component of the tear
film. It gained widespread application in lubricants, because
it effectively binds water, resists dehydration, and shows
excellent biocompatibility.6–8 Previous studies have shown
that SH protects corneal epithelial cells against damage,
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stimulates epithelial migration, and improves the optical
quality of the retinal image.6,9
Previous studies reported about the effectiveness of ocular
lubricants in protecting cornea from dehydration in a porcine
dry eye model,10 the tear film instability in a rabbit model.11
Previous clinical studies also showed that both SH and car-
boxymethylcellulose (CMC) improve the ocular surface,
stabilize precorneal tear film, and ameliorate the intensity of
dry eye symptoms.12,13
Topical 0.05% cyclosporine (CS) has an anti-
inflammatory and immunomodulatory mode of action and it
is an effective treatment for dry eye disorder.14 It showed
significant improvement in corneal and conjunctival staining
scores.14
However, to the best of our knowledge, there is no report
that compares the efficacy of SH and CS in dry eye syn-
drome. The present study was designed to evaluate the ef-
ficacy and safety of 0.1%, 0.15%, and 0.3% SH compared
with 0.05% CS in patients with dry eye. We selected 0.1%,
0.15%, and 0.3% concentrations of SH because they are
commercially available and commonly used for the treat-
ment of dry eye.
Methods
The study was conducted in accordance with the ethical
principles set forth in the Declaration of Helsinki and the
Good Clinical Practice Guidelines. The study protocol and
informed consent were reviewed and approved by the insti-
tutional review board (IRB) before initiation (IRB#SC
14MSMV0028). Written informed consent was obtained
from each patient before the start of the study, and power
analysis was performed to justify the number of patients en-
rolled in the study. The study was conducted at multiple
clinical sites. The name of the trial registry is CRIS (http://
cris.nih.go.kr), WHO ICTRP (International Clinical Trials
Registry Platform (www.who.int/ictrp), and the registration
number of the trial is KCT0001796.
Study design
This is a prospective, randomized, multicenter active-
controlled trial conducted in 3 phases: screening, evaluation,
and follow-up. As much as possible, the study was con-
ducted under masked conditions for the investigators; the
perfect masked conditions could not be accomplished be-
cause the instillation frequency and chemical properties
differ between SH and CS ophthalmic solution.
Eligible patients were allocated randomly to receive 0.1%
hyaluronic acid (SH) eye drop or 0.15% hyaluronic acid
(SH) eye drop or 0.3% hyaluronic acid (SH) eye drop or
0.05% cyclosporine (CS) eye drop. Central randomization
was adopted for assigning patients to each group using a
dynamic allocation of stratified centers.15
Patients in SH group received 0.1% hyaluronic acid oph-
thalmic suspension (Hyalein ophthalmic solution 0.1%;
Taejoon, Seoul, Korea) or 0.15% hyaluronic acid ophthalmic
suspension (New Hyaluni ophthalmic solution 0.15%; Tae-
joon, Seoul, Korea) or 0.3% hyaluronic acid ophthalmic
suspension (Hyaluni ophthalmic solution 0.3%; Taejoon,
Seoul, Korea), 1 drop in each eye 5–6 times daily. Patients in
CS group received 0.05% cyclosporine ophthalmic solution
(RESTASIS; Allergan, Inc., California), 1 drop in each eye
twice daily. For both groups, the total treatment period was 12
weeks, and examinations were conducted at week 6 and 12
after the start of treatment.
Study population
Eligible patients were 19 years of age or older who had
been diagnosed as dry eye syndrome within 3 months and
had dry eye-related symptoms that were present for more
than 3 months before the screening examination. Other in-
clusion criteria were as follows: (1) tear film break-up time
(TBUT) value of 5 s or less, (2) fluorescein corneal staining
(FCS) score of 4 or more by NEI scale, and (3) Schirmer I
test value at 5min of 10mm or less. These criteria needed to
be met at both the screening and baseline examinations.
Exclusion criteria included (1) anterior ocular disease
(such as neurotrophic keratitis or keratoconus), (2) contin-
ued use of eye drops, (3) patients who had a punctal plug or
had it removed within 1 month before the screening ex-
amination, and (4) patients who underwent an operation to
the ocular surface or intraocular surgery within 2 months
before the screening period.
The following drugs or therapies were prohibited from the
screening examination to the end of study treatment: ste-
roids; immunosuppressants; antihistamines; any prescription
or over-the-counter ophthalmic drugs; contact lenses; and
ocular surgery or any other treatment affecting the dynamics
of tear fluid, including its nasolacrimal drainage process.
Randomization
Patients were divided and assigned to 4 groups based on
simple randomization. Group 1 was treated with 0.1% SH
eye drops for 12 weeks. Group 2 was treated with 0.15% SH
eye drops for 12 weeks. Group 3 was treated with 0.3% SH
eye drops for 12 weeks. Group 4 was treated with 0.05% CS
eye drops for 12 weeks.
At the beginning of the treatment period, the subjects
were randomized corresponding to allocation codes gener-
ated for SH and CS using the permuted block method.
Participants were randomized sequentially at each site.
Assessment of outcome measures
Efficacy assessments. Efficacy was evaluated primarily
with an objective measure and secondarily with objective
and subjective measures. There was one primary objective
end point which is FCS score at week 12 (last observation).
Secondary objective end points were TBUT, lissamine green
conjunctival staining (LGCS) score, meibomian gland dys-
function (MGD) index, and Schirmer’s test value. Second-
ary subjective end point was ocular surface disease index
(OSDI) questionnaire for the grading of the symptom
score.16 The sum of the scores was used in the analysis. All
of these parameters were assessed at baseline, week 6, week
12, or at treatment discontinuation.
For FCS scores, 5 mL of 2% fluorescein solution was in-
stilled in the conjunctival sac as the patient blinked nor-
mally. Corneal staining was examined under standard
illumination using a slit-lamp microscope with a cobalt blue
filter. According to the National Eye Institute/Industry
Workshop report, the cornea was divided into 5 fractions.17
FCS scores were measured on a 0–3 point scale, in the
superior, inferior, nasal, temporal, and central corneal zones:
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0 (no staining), 1 (mild superficial stippling), 2 (moderate
punctate staining, including superficial abrasion of the cor-
nea), and 3 (severe abrasion or corneal erosion, deep corneal
abrasion or recurrent erosion). The total score was then
calculated.
For LGCS scores, 20mL of 1% lissamine green solution
was instilled in the conjunctival sac, and the conjunctiva
was divided into 6 fractions.17 Conjunctival staining was
evaluated under low illumination by slit-lamp microscopy
and was scored from 0 through 3 for each fraction, then
summed to calculate the total score.
For TBUT, 5 mL of 2% fluorescein solution was instilled
in the conjunctival sac, and TBUT was then evaluated by
slit-lamp microscopy. The elapsed time from a normal blink
to the first appearance of a dry spot in the tear film was
measured thrice.
Schirmer test was performed without anesthesia to mea-
sure tear volume as follows. A Schirmer test strip was
placed on the lower eyelid between palpebral conjunctiva
and bulbar conjunctiva without touching the cornea. The
tear volume then was measured for 5min. The length in
millimeters of tear fluid absorbed on the strip measured from
the edge of the strip was recorded as tear volume.
The expressibility of the meibum was scored by the ap-
plication of the digital pressure to the upper tarsus, and the
degree of ease with which the meibum was induced was
evaluated semiquantitatively as follows: 0, clear meibum
easily expressed; 1, cloudy meibum expressed with mild
pressure; 2, cloudy meibum expressed with more than
moderate pressure; and 3, meibum not expressed, even with
the hard pressure.18
The quality of the meibum was scored by the digital
pressure over 8 meibomian glands of the lower lids. The
meibum secretion was graded as follows: 0, clear; 1, cloudy;
2, cloudy with granular debris; and 3, thick like toothpaste.
Safety assessments. The safety variable was the occur-
rence of adverse events (AEs), determined at various visits
by means of physical signs and symptoms, external eye
examination, slit-lamp microscopy, visual acuity, intraocu-
lar pressure, and funduscopy.
Statistical analysis
All patients who were enrolled in the study were included
in the efficacy and safety analyses. Considering the multi-
plicity of the test, closed testing procedures were used to
verify noninferiority by FCS score. Noninferiority of SH to
CS was determined if the 95% confidence interval (CI) for
the intergroup difference was calculated, and if the upper
limit did not exceed the 0.34 inferiority margin. In addition,
intergroup comparison between SH and CS groups at week
12 was done using the t-test. Furthermore, an analysis of
change from baseline of FCS and LGCS score at each visit
and secondary end points was performed using the t-test or
Wilcoxon signed-rank test.
The incidence rates of AEs and adverse drug reactions
observed after starting the treatment period were tabulated
for each group, and intergroup homogeneity was analyzed
using Fisher’s exact test. The significance level for tests
related to safety and efficacy was 5% for both sides, with CI
of 95% on both sides. SAS software V.9.2 (SAS Institute,
Cary, NC) was used for statistical analysis.
Results
Participant characteristics
A total of 176 patients were allocated randomly to receive
1 of the 4 treatments: 43 patients entered the 0.1% SH
group, 41 patients entered the 0.15% SH group, 47 patients
entered the 0.3% SH group, and 45 patients entered the
0.05% CS group. Demographics and other baseline char-
acteristics are shown in Table 1. Of the total 176 partic-
ipants, 147 were female (83.52%), and the mean age –
standard deviation (SD) was 45.06 – 14.83 years.
Efficacy evaluation
Primary end point. There was a statistically significant
improvement in FCS score in all groups at week 6 and 12,
although no significant intergroup difference was shown.
The mean change from baseline to week 12 in FCS score
was -3.77 – 1.97 for the 0.1% SH group, -4.22 – 2.73 for the
Table 1. Initial Characteristics of Each Group with Dry Eye Syndrome Before Treatment
0.1% SH 0.15% SH 0.3% SH 0.05% CS P
Gender
Male 6 5 7 11 0.4063
Female 37 36 40 34
Age 44.14 – 13.86 46.20 – 13.98 44.77 – 16.17 45.22 – 15.42 0.8217
Main cause of dry eye
Tear deficient
Primary Sjo¨gren’s syndrome 1 0 0 0
Non-Sjo¨gren’s lacrimal disease (aging) 12 13 10 16 0.4678
Non-Sjo¨gren’s lacrimal disease (menopause) 0 1 1 0
Evaporative
Meibomian gland disease 11 12 13 16 0.5371
Lid surfacing/blinking abnormalities 2 4 8 6
Tear deficient + evaporative 17 11 15 7 0.2273
Data are presented as number and mean value– standard error.
Group 1 (0.1% SH): 0.1% sodium hyaluronate; group 2 (0.15% SH): 0.15% sodium hyaluronate; group 3 (0.3% SH): 0.3% sodium
hyaluronate; group 4 (0.05% CS): 0.05% cyclosporine.
CS, cyclosporine; SH, sodium hyaluronate.
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0.15% SH group, -3.52 – 2.15 for the 0.3% SH group, and
-3.60 – 3.04 for the 0.05% CS group (Fig. 1a). In the pri-
mary analysis, the upper limit was lower than the non-
inferiority margin of 0.34, and the mean change from
baseline in FCS scores verified noninferiority of 0.1% SH
and 0.15% SH to 0.05% CS. In addition, the 95% CI did not
include 0, indicating the significant improvement of 0.1%
and 0.15% SH. At week 12, there were more improvements
with 0.15% SH in the FCS scores although no significant
intergroup difference was shown.
Secondary end points
LGCS score. LGCS scores showed significant im-
provement compared with baseline in all groups and at all
time points. The mean change from baseline to week 12
in LGCS score was -2.72 – 3.25 for the 0.1% SH group,
-3.14 – 2.72 for the 0.15% SH group, -2.67 – 2.95 for the
0.3% SH group, and -2.51 – 2.95 for the 0.05% CS group
(Fig. 1b). At all estimations, there were no significant in-
tergroup differences. However, these scores in the 0.15%
SH group showed a tendency for better improvement com-
pared with the other groups at week 12.
TBUT and Schirmer I score. TBUT showed significant
improvement compared with baseline in all groups and at all
time points. The mean change from baseline to week 12 in
TBUT was 2.18 – 2.63 for the 0.1% SH group, 2.30 – 2.57
for the 0.15% SH group, 2.24 – 2.30 for the 0.3% SH group,
and 1.90 – 2.45 for the 0.05% CS group (P < 0.0001;
Fig. 2a). There was no statistically significant difference
between groups at week 6 and 12 (P > 0.05).
The mean change from baseline to week 12 in Schirmer
test results was 1.31 – 6.04 for the 0.1% SH group,
2.54 – 6.46 for the 0.15% SH group, 0.70 – 6.39 for the 0.3%
SH group, and 1.07 – 6.57 for the 0.05% CS group (Fig. 2b).
However, scores in the 0.15% SH group showed a signifi-
cant tendency for better improvement at week 12 compared
with the 0.1% SH, 0.3% SH, and 0.05% CS group
(P< 0.05). There was no statistically significant difference
in the improvement in Schirmer I score between groups at
week 6 and 12 (P > 0.05).
OSDI score. There was a statistically significant im-
provement in the mean change from baseline to week 6 and
12 in the OSDI score. The mean change from baseline
to week 12 was -12.39 – 19.21 for the 0.1% SH group,
-11.86– 14.48 for the 0.15% SH group, -12.07– 18.49 for
the 0.3% SH group, and -17.93– 20.58 for the 0.05% CS
group (P< 0.0001; Fig. 3). There was no statistically sig-
nificant difference in the improvement in OSDI between
groups at week 6 and 12 (P > 0.05).
There was no significant difference in all groups for
change from baseline to week 12 in parameters of MGD.
Safety evaluation
Treatment-related AEs were observed in 6 patients
(13.33%) in the 0.1% SH group, 9 patients (19.57%) in the
0.15% SH group, 6 patients (12.77%) in the 0.3% SH group,
and 15 patients (31.25%) in the 0.05% CS group. No sig-
nificant intergroup difference was shown. The most fre-
quently observed AE was ocular pain, which was observed
in 2 patients (4.44%) in the 0.1% SH group, 2 patients
(4.35%) in the 0.15% SH group, 1 patient (2.13%) in the
0.3% SH group, and in 2 patients (4.17%) in the 0.05% CS
group. All eye disorders were mild in severity and resolved
either with appropriate treatment or with no treatment. No
deaths and no serious AEs were observed in this study.
FIG. 1. Fluorescein (a) and lissa-
mine green (b) staining score chan-
ges from the baseline value. Mean
value – standard error. The decrease
in fluorescein and lissamine green
staining scores in all groups was
statistically significant atweek 6 and
12 (P < 0.05).
FIG. 2. TBUT (a) and Schirmer I
score (b) change from the baseline.
Mean value – standard error. The
increase in TBUT (s) in all groups
was statistically significant at week
6 and 12 (P < 0.05). There was no
significant difference in the increase
in the TBUT between groups at
week 6 and 12. The increase in the
Schirmer I score in 0.15% SH was
statistically significant at week 12
(P < 0.05). SH, sodium hyaluronate;
TBUT, tear film break-up time.
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Discussion
Patients with dry eye complain of blurriness and glare
although they have normal visual acuity.19 This deteriora-
tion in vision may be the consequence of the tear film
breakup, causing an irregular tear surface.20 In addition, tear
hyperosmolarity, ocular surface inflammation, and damage
to the ocular surface were observed in patients with dry
eye.21
In this phase 4 trial, SH eye drop demonstrated statisti-
cally significant efficacy and improvements as 0.05% CS for
the treatment of dry eye. SH eye drop was effective at im-
proving both the objective signs and the subjective symp-
toms of dry eye. Study data were obtained from a population
representative of that seen in normal clinical practice, be-
cause dry eye commonly affects women who are middle-
aged and older.22,23
Our study revealed that the effects of 0.1% SH, 0.15%
SH, and 0.3% SH versus 0.05% CS were thoroughly com-
parable during the whole study period. In addition, in
within-group analysis, dry eye patients who received 0.15%
SH exhibited better improvement versus baseline in FCS
score at week 12 although it was not statistically significant.
FCS is a measurement of corneal damage reflecting corneal
epithelium integrity and LGCS reflecting conjunctival epi-
thelium integrity. Therefore, these improvements at week 6
and 12 showed that 0.1% SH, 0.15% SH, 0.3% SH, and
0.05% CS objectively improved the health of the ocular
surface in the primary analysis. Our results are in good
agreement with previous clinical data, which reported that
SH-containing eye drops stimulate healing of the corneal
epithelium.24
TBUT is considered a surrogate measure of tear-film
stability. The improvements in TBUT with use of SH sug-
gest improved integrity of the tear film, which can prevent
evaporation, hyperosmolarity, and progression of dry eye
disease due to its rheological, mucomimetic, and water-
retention properties.25
In addition to its benefits on objective measures, 0.1%
SH, 0.15% SH, and 0.3% SH were as effective as 0.05% CS
on subjective outcomes, showing improvement in symp-
toms. The subjective improvements in dry eye symptoms
observed in this study were supported by improvements in
clinical outcome measures. Evaluating the treatment success
in dry eye syndrome is a major challenge because of the
weak correlation between signs and symptoms in dry eye
syndrome, and the high variability of objective signs such as
Schirmer test.26 Therefore, the assessment of efficacy using
subjective symptoms, as well as objective signs, is particu-
larly important in patients with dry eye.
However, OSDI scores in the 0.05% CS group showed a
tendency for better improvement compared with the other
groups although the intergroup difference was not signifi-
cant. This finding could be partly explained by the higher
degrees of dry eye symptoms in the CS group at the be-
ginning of the study although it was not statistically sig-
nificant. Schirmer test values in the 0.15% SH group showed
a significant tendency for better improvement at week 12
compared with those of the 0.1% SH, 0.3% SH, and 0.05%
CS group (P < 0.05). This is most likely to be attributed to
unique anti-inflammatory properties of SH indirectly lead-
ing to tear secretion.
Previous study found that SH and CMC had significantly
higher ocular surface retention times than physiological
saline solution, and of these, 0.3% SH had the highest
ability to protect the corneal epithelial cells from desic-
cation, which was concentration dependent.27 However, in
this study, the efficacy of SH eye drops did not reveal
concentration dependent results. The difference between
our results and previous study may come from dissim-
ilarities in type and dry eye severity. The participants in
this study had a combined aqueous tear-deficient and
evaporative dry eye with the severity of moderate to severe
grading according to DEWS classification.2 Therefore, a
single dose of SH did not seem to be significantly effective
in moderate to severe dry eye patients. If our study en-
rolled patients with mild dry eye, concentration dependent
results may have been shown. In addition, only 0.05% CS
without any kinds of artificial tears is insufficient to allow
epithelial healing and reduce dry eye symptoms in mod-
erate to severe dry eye disease and is, therefore, unlikely to
cause noticeable alterations after treatment. Artificial tears
are typically recommended to use together with anti-
inflammatory or immunomodulatory ophthalmic solutions
as primary treatment options for moderate dry eye and in
combination with other therapies for severe dry eye in
clinical practice.28
0.1% SH, 0.15% SH, 0.3% SH, and 0.05% CS were well
tolerated. All AEs were resolved by the end of the study
period. Some of the AEs were not distinguishable from
exacerbations or fluctuations of dry eye symptoms clearly.
No serious events occurred and no safety issues were
raised.
This study has some limitations. First, the duration was
short. It may be insufficient to compare the impact of the SH
and cyclosporine treatment on long-term dry eye disease
since CS eye drop is believed to effect subconjunctival in-
flammation by preventing the recruitment of T cells, which
may take 3–6 months. However previous study has shown
that although CS eye drop improves objective and subjective
measures of the dry eye, it may take up to 4–8 weeks to
show its maximum effect.29 Therefore even though this
study is limited in duration, it still justifies the results. A
larger and longer study is warranted to more thoroughly
FIG. 3. OSDI score change from the baseline. Mean
value – standard error. The decrease in the OSDI score in all
groups was statistically significant at week 6 and 12
(P < 0.05). OSDI, ocular surface disease index.
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address important clinical issues, including the effects of SH
and CS eye drops on controlling ocular surface inflamma-
tion, reducing tear hyperosmolarity, and repairing corneal
epithelium. Second, the difference of instillation frequency
between SH and CS may influence the outcomes. Third, the
lack of a placebo for the SH and CS ophthalmic solution
could be the weakness in this study. Further studies will be
required to investigate whether the improvements reported
with SH are maintained in the longer term.
Conclusions
In conclusion, this is the first study to evaluate the ef-
ficacy and safety of the 0.1% SH, 0.15% SH, and 0.3% SH
compared with 0.05% CS in patients with dry eye. Our
study showed that a 12-week, 4–6 times daily treatment
with 0.1% SH, 0.15% SH, and 0.3% SH was as effective as
0.05% CS in improving the objective signs and subjective
symptoms of dry eye. These results suggest that it may lead
to improved treatment of corneal and conjunctival epithe-
lial damage and improvement in symptoms in patients with
dry eye. Such efficacy, in addition to the well-tolerated
profile of 0.1% SH, 0.15% SH, and 0.3% SH, makes them
potentially useful treatment options for dry eye in clinical
practice.
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